MaaT Pharma

MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity...

Microbiome,microbiota,microbiology,pharma,gvhd,leukemia,dysbiosis,symbiosis,biotech,oncology,cancer,gut microbiota,allo-hsct,and gut microbiome

Maat pharma operates in the Biotechnology research industry.

Maat pharma's revenue is 1m - 10m

Maat pharma has 51 - 200 employees.